Jan 09th 2013 - Edison Investment Research today published a report on Genmab entitled "Stars Are Realigning". In summary, the report says:
Genmab’s daratumumab has the potential to be a game changer. Activity of the anti-CD38 antibody in myeloma represents a new and complementary mechanism of action, meeting a major unmet medical need. Heavily pre-treated multiple myeloma patients extraordinarily achieved a partial response after short single-agent exposure. Although early stage, the data is sufficiently impressive for J&J and Genmab to communicate an ambitious clinical trial programme this year across a variety of haematological cancers, targeting a market opportunity of c $9bn.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »